RS52253B - Upotreba l-karnitina za lečenje kardiovaskularnih bolesti - Google Patents

Upotreba l-karnitina za lečenje kardiovaskularnih bolesti

Info

Publication number
RS52253B
RS52253B RS20120095A RSP20120095A RS52253B RS 52253 B RS52253 B RS 52253B RS 20120095 A RS20120095 A RS 20120095A RS P20120095 A RSP20120095 A RS P20120095A RS 52253 B RS52253 B RS 52253B
Authority
RS
Serbia
Prior art keywords
carnitine
acid
glucose
glucose solution
patients
Prior art date
Application number
RS20120095A
Other languages
English (en)
Serbian (sr)
Inventor
Aleardo Koverech
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of RS52253B publication Critical patent/RS52253B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20120095A 2004-07-13 2005-06-21 Upotreba l-karnitina za lečenje kardiovaskularnih bolesti RS52253B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000346A ITRM20040346A1 (it) 2004-07-13 2004-07-13 Uso della l-carnitina per il trattamento di patologie cardiovascolari.
PCT/EP2005/006657 WO2006005415A2 (en) 2004-07-13 2005-06-21 Use of l-carnitine and glucose for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
RS52253B true RS52253B (sr) 2012-10-31

Family

ID=34971575

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120095A RS52253B (sr) 2004-07-13 2005-06-21 Upotreba l-karnitina za lečenje kardiovaskularnih bolesti

Country Status (21)

Country Link
US (2) US7879908B2 (enExample)
EP (1) EP1773314B1 (enExample)
JP (1) JP5230195B2 (enExample)
KR (1) KR101296479B1 (enExample)
CN (2) CN101087602B (enExample)
AT (1) ATE542529T1 (enExample)
AU (1) AU2005262050B2 (enExample)
BR (1) BRPI0513303A8 (enExample)
CA (1) CA2569888C (enExample)
CY (1) CY1112686T1 (enExample)
DK (1) DK1773314T3 (enExample)
ES (1) ES2380913T3 (enExample)
HR (1) HRP20120178T1 (enExample)
IT (1) ITRM20040346A1 (enExample)
ME (1) ME01345B (enExample)
MX (1) MXPA06014665A (enExample)
PL (1) PL1773314T3 (enExample)
PT (1) PT1773314E (enExample)
RS (1) RS52253B (enExample)
SI (1) SI1773314T1 (enExample)
WO (1) WO2006005415A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086543A1 (es) * 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1120033B (it) * 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
JPS6415220A (en) 1987-07-06 1989-01-19 Mitsubishi Electric Corp Tension control device for utilizing maximum torque and maximum electric current of winding motor
JPH06102624B2 (ja) * 1990-08-10 1994-12-14 アース製薬株式会社 非心臓由来の不整脈防止薬
IT1261695B (it) * 1993-06-02 1996-05-29 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e alcanoil l-carnitine nella conservazione del sangue per trasfusioni e soluzioni stabilizzatrici che le contengono.
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
WO2000030637A1 (en) * 1998-11-26 2000-06-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia
KR100642731B1 (ko) * 1999-10-11 2006-11-03 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 의료용 용액에서 삼투제로서 ｌ-카르니틴 및 그의알카노일 유도체의 용도
JP4674046B2 (ja) * 2002-04-01 2011-04-20 ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ グルコース利用を刺激する化合物および使用方法
ITRM20030178A1 (it) 2003-04-17 2004-10-18 Sigma Tau Ind Farmaceuti Uso della l-carnitina per il trattamento di patologie cardiovascolari.

Also Published As

Publication number Publication date
ITRM20040346A1 (it) 2004-10-13
CN101087602B (zh) 2011-09-14
HK1166003A1 (zh) 2012-10-19
MXPA06014665A (es) 2007-03-12
ME01345B (me) 2012-10-31
CN102349923A (zh) 2012-02-15
HRP20120178T1 (hr) 2012-05-31
JP5230195B2 (ja) 2013-07-10
BRPI0513303A (pt) 2008-05-06
KR20070039541A (ko) 2007-04-12
WO2006005415A2 (en) 2006-01-19
ES2380913T3 (es) 2012-05-21
CA2569888C (en) 2013-08-13
CN102349923B (zh) 2016-04-27
US20070207970A1 (en) 2007-09-06
US8394854B2 (en) 2013-03-12
KR101296479B1 (ko) 2013-08-13
ATE542529T1 (de) 2012-02-15
PT1773314E (pt) 2012-03-29
AU2005262050B2 (en) 2011-02-24
DK1773314T3 (da) 2012-05-07
PL1773314T3 (pl) 2012-06-29
HK1113542A1 (en) 2008-10-10
AU2005262050A1 (en) 2006-01-19
EP1773314A2 (en) 2007-04-18
US7879908B2 (en) 2011-02-01
US20110086917A1 (en) 2011-04-14
CY1112686T1 (el) 2016-02-10
WO2006005415A3 (en) 2006-05-26
EP1773314B1 (en) 2012-01-25
CA2569888A1 (en) 2006-01-19
SI1773314T1 (sl) 2012-04-30
BRPI0513303A8 (pt) 2017-12-26
CN101087602A (zh) 2007-12-12
JP2008517872A (ja) 2008-05-29

Similar Documents

Publication Publication Date Title
US6218366B1 (en) Method for raising the hypoxic threshold
AU2010202396A1 (en) Use of L-carnitine for the treatment of cardiovascular diseases
Markov et al. Hemodynamic effects of fructose 1, 6-diphosphate in patients with normal and impaired left ventricular function
ES2250749T3 (es) Uso de una composicion combinada que comprende propionil l-carnitina y otros farmacos para el tratamiento de la disfuncion erectil.
US6881739B1 (en) Use of cortisol antagonists in the treatment of heart failure
RS52253B (sr) Upotreba l-karnitina za lečenje kardiovaskularnih bolesti
JP2006523685A5 (enExample)
HK1113542B (en) Use of l-carnitine and glucose for the treatment of cardiovascular diseases
HK1166003B (en) Use of l-carnitine and glucose for the treatment of cardiovascular diseases
HK1132174A (en) Use of l-carnitine for the treatment of cardiovascular diseases
JP2008517872A5 (enExample)